๐ŸŽFREE MT2 VIAL WITH ELIGIBLE ORDERS โ€” $60 VALUE ยท LIMITED TIME
Home Products COA Library Research Insights About FAQ My Account
Products / AOD 9604
99.4% PURITY RESEARCH USE ONLY

AOD 9604 10mg

$159.95 $159.95 / vial
AUSTRALIA'S TRUSTED CHOICE โœฆโœฆโœฆโœฆโœฆ
Select Strength
FREE MT2 VIAL WITH ELIGIBLE ORDERS Complimentary $60 value ยท Claim in cart ยท While stocks last ยท Research use only
Bundle quantity
Same-day dispatch Orders placed before 2pm AEST on business days
Australia Post Standard 2โ€“5 business days ยท Express 1โ€“3 business days ยท Free Express shipping on orders over $100
Shipment protection included Lost or damaged in transit? We replace it, no questions asked.
Pay in 4 with afterpay Interest-free instalments over 6 weeks. Afterpay is available on our secure payment page. Select "Place Order" at checkout to view your available payment methods. Eligibility and terms apply.
ACCEPTED PAYMENT METHODS
VISA mastercard AMERICAN
EXPRESS
Overview

HALO BIO ยท COMPOUND RESEARCH PROFILE
AOD-9604 10mg
Modified human growth hormone fragment research

Explore the molecular structure of AOD-9604, its relationship to the C-terminal region of human growth hormone and published investigations into lipid metabolism, fat oxidation and experimental metabolic signalling.

AOD-9604, also known as Tyr-hGH 177-191, is a synthetic 16-amino-acid peptide derived from the C-terminal region of human growth hormone. It was developed for experimental investigations into lipid metabolism and related metabolic pathways.

Halo Bio supplies AOD-9604 10mg-labelled lyophilised research material. The nominal vial specification does not independently establish batch identity, purity or measured peptide content.

PRODUCT & RESEARCH SNAPSHOT

AOD-9604 at a glance

Scientific name: AOD-9604
Alternative names: AOD9604, Tyr-hGH 177-191, LAT8881
Classification: Modified C-terminal human growth hormone fragment
Peptide length: 16 amino acids
Sequence: YLRIVQCRSVEGSCGF
Structural feature: Intramolecular disulphide bridge
Molecular formula: C78H123N23O23S2 (AOD-9604 acetate reference record)
Molecular weight: Approximately 1,815.1 g/mol (acetate reference record)
Labelled strength: 10mg per vial
Presentation: Lyophilised laboratory research material
Research areas: Lipid metabolism, lipolysis, fat oxidation and energy metabolism
Fulfilment: Melbourne-held stock ยท eligible same-day dispatch before 2pm

MOLECULAR RESEARCH

A modified 16-amino-acid hGH fragment

AOD-9604 is based on the 177-191 region of human growth hormone, with an additional N-terminal tyrosine. Unlike the full-length 191-amino-acid hormone, AOD-9604 is a much shorter molecule investigated for selected metabolic properties.

The peptide contains two cysteine residues connected by a disulphide bond. This structural feature forms part of the molecule’s defined chemical identity.

PATHWAY 01

Lipolysis research

Preclinical investigations have measured the breakdown of stored lipids and associated glycerol release in experimental metabolic models.

PATHWAY 02

Fat oxidation

Experimental studies investigated changes in fat oxidation, a process through which fatty acids contribute to energy metabolism.

PATHWAY 03

Receptor signalling

Researchers examined growth hormone receptor activity and beta-3 adrenergic-related signalling to better understand the fragment’s experimental mechanisms.

These are experimental research pathways, not established evidence that AOD-9604 causes weight loss or provides metabolic benefits in humans.

PUBLISHED SCIENTIFIC EVIDENCE

What has AOD-9604 research investigated?

AOD-9604 has been investigated in preclinical models and historical human clinical development programmes. Early experimental findings and later human outcomes need to be considered separately.


Heffernan et al. ยท International Journal of Obesity (2001)

Preclinical investigations examined fat oxidation, glycerol release and body-weight gain in experimental obesity models. Results suggested metabolic activity under the study conditions. Separate cell assays examined the fragment’s relationship to full-length growth hormone signalling.


Heffernan et al. ยท Endocrinology (2001)

A separate study investigated chronic AOD-9604 exposure in experimental obesity models, including beta-3 adrenergic receptor-related measurements. Findings indicated that its proposed mechanism was more complex than direct beta-3 receptor activation alone.


Stier et al. ยท Journal of Endocrinology and Metabolism (2013)

A publication summarised six historical randomised, double-blind, placebo-controlled human studies involving 893 adults. These investigations used oral or intravenous study products and examined safety and tolerability under controlled trial conditions.


Later obesity-development findings

A later 24-week Phase 2b obesity programme involving 536 participants did not demonstrate statistically significant weight loss. Development for that indication was discontinued. This is an important limitation when interpreting the earlier preclinical results.

Historical clinical studies used different formulations and routes from this separate lyophilised research vial. Their results do not verify the safety or performance of Halo Bio material.

MOLECULAR COMPARISON

AOD-9604 vs Human Growth Hormone

Although AOD-9604 was developed from a sequence region of human growth hormone, the two molecules have substantially different structures and cannot be treated as interchangeable.

Characteristic AOD-9604 Human Growth Hormone
Peptide length 16 amino acids 191 amino acids
Molecular classification Modified C-terminal fragment Full-length hormone
Structural relationship Based on hGH 177-191 with an added tyrosine Complete hGH sequence
Research focus Experimental lipid metabolism Growth hormone physiology and endocrine signalling
Interchangeable? No No

Findings involving the full-length hormone should not be attributed to its modified fragment without supporting experimental evidence.

AUSTRALIAN FULFILMENT

Melbourne stock. Nationwide dispatch.

Halo Bio holds stock in Melbourne and offers same-day dispatch for eligible in-stock orders placed before 2pm on business days, subject to payment confirmation. Tracking information is provided during fulfilment, with delivery times dependent on destination and carrier.

FREQUENTLY ASKED QUESTIONS

AOD-9604 research FAQs

What is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide based on the C-terminal region of human growth hormone. It is also known as Tyr-hGH 177-191.

What does AOD stand for?

AOD originally referred to Anti-Obesity Drug, reflecting the compound’s historical research-development programme. The name does not establish an approved medical use.

What is AOD-9604 studied for?

Preclinical work investigated lipid metabolism, lipolysis, fat oxidation and energy-related measurements. Historical human development programmes also examined obesity-related outcomes.

Is AOD-9604 the same as human growth hormone?

No. Human growth hormone contains 191 amino acids, whereas AOD-9604 is a modified 16-amino-acid fragment with different molecular properties.

Does AOD-9604 research prove weight loss in humans?

No. Despite encouraging findings in some preclinical studies, a later Phase 2b obesity-development programme did not demonstrate statistically significant weight loss.

What is the AOD-9604 amino-acid sequence?

The reported sequence is YLRIVQCRSVEGSCGF, containing 16 amino-acid residues and a disulphide bridge between two cysteines.

What does the 10mg vial label mean?

It represents the nominal quantity of AOD-9604 research material. The label alone does not establish measured content or purity.

Can AOD-9604 be mixed with bacteriostatic water?

Solvent compatibility must be established for the specific research formulation. Do not assume that another supplier’s acidic-solution instructions or generic reconstitution charts apply to Halo Bio material. Follow verified product-specific laboratory handling documentation.

Is this product suitable for human or animal use?

No. Halo Bio supplies this material exclusively for laboratory research, not for consumption, injection, self-administration or clinical treatment.

When will my order be dispatched?

Eligible in-stock orders placed before 2pm on business days are dispatched from Melbourne the same day following payment confirmation.

SCIENTIFIC REFERENCES

Independent scientific publications

  1. Heffernan MA et al. Chronic treatment with human growth hormone or a modified C-terminal fragment and effects on fat oxidation in experimental obesity models. International Journal of Obesity, 2001.
  2. Heffernan M et al. The effects of human GH and its lipolytic fragment AOD9604 on lipid metabolism in experimental models. Endocrinology, 2001.
  3. Stier H et al. Safety and tolerability of the hexadecapeptide AOD9604 in human clinical trials. Journal of Endocrinology and Metabolism, 2013.
  4. Misra M. Obesity pharmacotherapy: current perspectives and future considerations. Therapeutic Advances in Endocrinology and Metabolism, 2013.
  5. PubChem. AOD-9604 acetate, CID 168310522.
    View molecular record โ†—

Research references describe historical experimental material and clinical formulations. They do not constitute laboratory verification of Halo Bio’s current product batch.

Laboratory research use only.

Not intended for human or animal consumption, injection, self-administration, diagnostic use or clinical treatment. Published experimental findings do not establish the identity, purity, sterility, safety or performance of this separately supplied AOD-9604 material. Refer to batch-specific documentation and verified laboratory handling instructions where available.

Order total $159.95